Literature DB >> 32524018

SPONTANEOUS CEREBROSPINAL FLUID LEAK AFTER INITIATION OF DOPAMINE AGONIST THERAPY IN MACROPROLACTINOMAS: TWO CASE REPORTS AND A LITERATURE REVIEW.

Jonea Lim, Mitali Talsania, Madona Azar.   

Abstract

OBJECTIVE: To describe 2 spontaneous cerebrospinal fluid (CSF) leaks complicating treatment of macroprolactinoma (MPRL) with dopamine agonist (DA) therapy.
METHODS: We present the 2 cases of spontaneous, DA-related CSF leaks. Prolactin levels were used to assess hyperprolactinemia. Beta-2 transferrin was tested in rhinorrhea fluid, and magnetic resonance imaging was used to assess the sella.
RESULTS: Case 1 was a 45-year-old woman with a history of MPRL, recently started on bromocriptine at 15 mg/day, presented with clear rhinorrhea, headache, and nuchal rigidity. Magnetic resonance imaging showed a large sellar lesion extending into the cavernous sinuses, posterior sphenoid sinuses, and suprasellar cistern. Computed tomography revealed areas concerning for bony erosion, likely representing leak sites, and the rhinorrhea fluid was positive for beta-2 transferrin, confirming the CSF source. Empiric antibiotics for meningitis were given and she underwent urgent neuroendoscopic, transsphenoidal CSF leak repair and debulking of the pituitary mass. Case 2 was a 55-year-old man with a 10-year history of untreated MPRL who was started on bromocriptine at 5 mg/day 2 weeks prior to admission. He presented with clear rhinorrhea and a metallic taste in his mouth, worse with the Valsalva maneuver. Imaging confirmed clinical suspicion and he was taken for surgery. A high-flow CSF leak was encountered once the tumor was debulked. This was repaired with an abdominal fat pad graft. Both patients developed diabetes insipidus and required postoperative adjuvant DA therapy.
CONCLUSION: Spontaneous CSF leaks can complicate medical therapy of large MPRL with underlying skull defects, typically within weeks of initiation of DA. This should prompt clinicians to educate patients about the symptoms of potential CSF rhinorrhea and encourage them to promptly report them.
Copyright © 2020 AACE.

Entities:  

Year:  2020        PMID: 32524018      PMCID: PMC7282151          DOI: 10.4158/AACR-2019-0372

Source DB:  PubMed          Journal:  AACE Clin Case Rep        ISSN: 2376-0605


  11 in total

Review 1.  CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas.

Authors:  K S Leong; P M Foy; A C Swift; S L Atkin; D R Hadden; I A MacFarlane
Journal:  Clin Endocrinol (Oxf)       Date:  2000-01       Impact factor: 3.478

2.  The epidemiology of prolactinomas.

Authors:  Antonio Ciccarelli; Adrian F Daly; Albert Beckers
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  Role of E-cadherin, alpha-, beta-, and gamma-catenins, and p120 (cell adhesion molecules) in prolactinoma behavior.

Authors:  Zhi Rong Qian; Chiun Chei Li; Hiroyuki Yamasaki; Noriko Mizusawa; Katsuhiko Yoshimoto; Shozo Yamada; Takashi Tashiro; Hidehisa Horiguchi; Shingo Wakatsuki; Mitsuyoshi Hirokawa; Toshiaki Sano
Journal:  Mod Pathol       Date:  2002-12       Impact factor: 7.842

Review 4.  Medically induced CSF rhinorrhea following treatment of macroprolactinoma: case series and literature review.

Authors:  Tomáš Česák; Pavel Poczos; Jaroslav Adamkov; Jiří Náhlovský; Petra Kašparová; Filip Gabalec; Petr Čelakovský; Ondrej Choutka
Journal:  Pituitary       Date:  2018-12       Impact factor: 4.107

5.  Bromocriptine treatment of prolactinomas.

Authors:  S L Aronoff; W H Daughaday; E R Laws
Journal:  N Engl J Med       Date:  1979-06-14       Impact factor: 91.245

Review 6.  Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.

Authors:  Shlomo Melmed; Felipe F Casanueva; Andrew R Hoffman; David L Kleinberg; Victor M Montori; Janet A Schlechte; John A H Wass
Journal:  J Clin Endocrinol Metab       Date:  2011-02       Impact factor: 5.958

7.  Role of matrix metalloproteinase 9 in pituitary tumor behavior.

Authors:  H E Turner; Z Nagy; M M Esiri; A L Harris; J A Wass
Journal:  J Clin Endocrinol Metab       Date:  2000-08       Impact factor: 5.958

8.  Thrombin receptor overexpression in malignant and physiological invasion processes.

Authors:  S Even-Ram; B Uziely; P Cohen; S Grisaru-Granovsky; M Maoz; Y Ginzburg; R Reich; I Vlodavsky; R Bar-Shavit
Journal:  Nat Med       Date:  1998-08       Impact factor: 53.440

9.  Giant prolactinomas: are they really different from ordinary macroprolactinomas?

Authors:  Etual Espinosa; Ernesto Sosa; Victoria Mendoza; Claudia Ramírez; Virgilio Melgar; Moisés Mercado
Journal:  Endocrine       Date:  2015-11-11       Impact factor: 3.633

10.  Nonsurgical cerebrospinal fluid rhinorrhea in invasive macroprolactinoma: incidence, radiological, and clinicopathological features.

Authors:  S G I Suliman; A Gurlek; J V Byrne; N Sullivan; G Thanabalasingham; S Cudlip; O Ansorge; J A H Wass
Journal:  J Clin Endocrinol Metab       Date:  2007-07-10       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.